epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Daytrana
    methylphenidate transdermal
  • remove Estarylla
    norgestimate/ ethinyl estradiol
  • remove Fiorinal
    butalbital/ aspirin/ caffeine
  • remove mesna
    generic

multicheck MultiCheck Results - 5 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Estarylla (norgestimate/ ethinyl estradiol) + Fiorinal (butalbital/ aspirin/ caffeine)

Avoid/Use Alternative


ethinyl estradiol (contraceptive) + butalbital

use additional non-hormonal or alternative contraception during and x28 days after butalbital tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced)

norgestimate (contraceptive) + butalbital

use additional non-hormonal or alternative contraception during and x28 days after butalbital tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

Monitor/Modify Tx


ethinyl estradiol (contraceptive) + caffeine

monitor BP; avoid excessive caffeine intake: combo may incr. caffeine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

Monitor/Modify Tx

Smiley face Smiley face Daytrana (methylphenidate transdermal) + Estarylla (norgestimate/ ethinyl estradiol)

Monitor/Modify Tx


methylphenidate + ethinyl estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

Smiley face Smiley face Daytrana (methylphenidate transdermal) + Fiorinal (butalbital/ aspirin/ caffeine)

Monitor/Modify Tx


methylphenidate + caffeine

monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

Additional Considerations

Smiley face Smiley face methylphenidate in Daytrana

add MAO inhibitor to Interaction Check if recent (14 days) use

avoid combo with beverages or products containing ethanol and some ER methylphenidate formulations (including capsule, chewable, oral suspension, ODT); combo may incr. methylphenidate release rate, levels, risk of adverse effects, decr. duration of efficacy

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information